Cleave Therapeuticsincis A Biopharmaceutical Company Based In San Franciscofounded In 2011The Company Specializes In Targeting Valosin Containing Proteinvcp P97To Develop Treatments For Cancer And Neurodegenerative Diseasescleave Has Raised A Total Of $103 Million In Funding And Operates As A Privately Held Entity Cleave S Lead Productcb 5339Is A Second Generationoral Vcp P97 Inhibitor Currently In A Phase 1 Clinical Study For Acute Myeloid Leukemiaamland Myelodysplastic Syndromemds The Company Is Also Engaged In Preclinical Programs Aimed At Solid Tumors And Neurodegenerative Diseasesfocusing On Enhancing Mitochondrial Healthcleave Collaborates With The National Cancer Institute And Other Academic Institutions To Advance Its Research And Clinical Development Efforts
